CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 18 enrolled
Drug / intervention
AZD2014drug
Likely dose
Not stated in record
Key inclusion· 8
  • ✓Confirmed diagnosis of NF2 by NIH or Manchester criteria or NF2 gene mutation detection
  • ✓Progressive or symptomatic meningioma with ≥20% volume increase or ≥3 mm growth over past 2 years
  • ✓Target meningioma not amenable to surgery due to patient preference or high surgical risk
  • ✓Measurable disease: at least one meningioma ≥1.0 ml on contrast-enhanced MRI within 28 days of registration
Key exclusion· 14
  • ✕Prior chemotherapy, biological therapy, or radiation within 21 days (investigational monoclonal antibody within 3 months; nitrosoureas/mitomycin C within 6 weeks)
  • ✕Unresolved Grade >1 toxicities (except alopecia) from prior anti-tumor treatment
  • ✕Major surgery within 4 weeks or minor surgery within 14 days before first dose (excluding tumor biopsies)
  • ✕Prior meningioma progression during mTORC1/2 inhibitor treatment (but not mTORC1 inhibitors like everolimus)

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02831257
NCT02831257Phase 2Completed
CompareCT.gov

A Single Arm Phase 2 Study of the Dual mTORC1/mTORC2 Inhibitor AZD2014 Provided on an Intermittent Schedule for Neurofibromatosis 2 Patients With Progressive or Symptomatic Meningiomas

Massachusetts General Hospital·interventional·Posted Jul 13, 2016·Updated Jun 13, 2022

In Brief

A Phase 2 clinical trial evaluating AZD2014 for Neurofibromatosis 2 and Meningioma. Completed, enrolled 18 participants across 2 sites.

Detailed Summary

The goal of this clinical research study is to learn if the study drug AZD2014 can shrink growing or symptomatic meningiomas.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeurofibromatosis 2, Meningioma
CountriesUnited States
CollaboratorsAstraZeneca, United States Department of Defense

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJul 13, 2016
Enrollment StartAug 31, 2016
Primary CompletionMay 31, 2019
Study CompletionOct 1, 2020
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 10.0 years ago

Interventions

AZD2014drug